CMS Open Payments · Program Year 2024
Pfizer S.a.
Pfizer S.a. reported $11,940.00 across General Payments, Research, and Ownership to 3 physicians and teaching hospitals across 3 transactions.
- $11.9K
- All-tracks total
- 3
- Transactions
- 3
- Recipients
- #1617
- of 1,925 companies
Pfizer S.a. reported $11,940.00 across all CMS Open Payments tracks (General + Research + Ownership) to 3 physicians and teaching hospitals in Program Year 2024 - ranking #1617 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $11,940.00, averaging $4.0K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pfizer-s-a Pfizer S.a.
$11.9K · #1617/1,925 · 0.0% industry · PY2024
- TOT $11.9K
- RANK #1617
- SHARE 0.0%
- TXN 3
- RCP 3
- CAT 1
- GEN $11.9K
- TOP1 60.6%
- PY 2024
Volume peers
Nearest volume peer: Blue Surgical Llc ($12.0K)
Pfizer S.a. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Pfizer S.a.
$11,940.00: that is what Pfizer S.a. reported in payments to 3 physicians and teaching hospitals during Program Year 2024, spread across 3 transactions ($4.0K per transaction, $4.0K per recipient). The company sits at rank #1617 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
"Compensation for Services Other Than Consulting" leads the 1-category general-payment breakdown below at $11.9K (100.0% of General Payments, 3 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Pfizer S.a. made 1 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $11.9K, 100.0% of General Payments.
How Pfizer S.a. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $11.9K | 3 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $11,940.00 (100.0%) of $11,940.00 in this company's General Payments records across 3 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pfizer S.a.
The five named recipients with the highest reported General Payments from this company
- 1
Deborah Friedman
$7,240.00 across 1 reported transactions
- 2
Andrew Charles
$2,700.00 across 1 reported transactions
- 3
Richard Lipton
$2,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pfizer S.a.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pfizer S.a..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pfizer S.a..
Showing 6 of 1,924 companies with CMS-reported payment data.
Astellas Pharma Europe BV
Music City Medical Technologies, LLC
Dutch Ophthalmic Research Center (International) B.V.
Amnio Technology, LLC
Smaio USA Corporation
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.